Since December 2010
T.O.M. Life Science Consulting
Thomas Mertenskoetter & Associates
Director
We support the pharmaceutical industry and global health field advancing their response to
communicable diseases
Jan. 2008 to Nov. 2010
International Partnership for Microbicides (HIV prevention)
Executive Director External Relations Europe
- Leading IPM’s overall Resource Development engagement in Europe
- Coordination of the relationships with IPM’s European donors and Civil Society partners
- Scientific representation of IPM in Europe
- Supporting cooperation with industry partners, clinical and academic collaborators
- Leading Access Working Group and coordinating the access to microbicides related research and activities
- Leading IPM’s Tenofovir Gel Product Team
Jan. 2002 to Jun. 2007
Gilead Sciences Germany
Director Medical Affairs
- Leading medical/clinical department with 8 FTEs
- Scientific support of launch and commercialisation of Viread (tenofovir), Emtriva (emtricitabin), Truvada (FDC tenofovir and emtricitabin), Hepsera (adefovir) and AmBisome (liposomal amphotericin B)
- Responsible for development and coordination of scientific and medical marketing strategy
- Responsible for design, development and implementation of local clinical development plan
- Medical lead and medical monitor in clinical trials
- Medical support of global clinical R&D
- Responsible for implementation of KOL management with setup of scientific advisory boards
- Setup and supervision of Medical Information function
- “Qualified scientific person responsible” (Informationsbeauftragter) according German drug law
- Development of annual educational programs for investigators on GCP and observational databases
- Representation of Gilead headquarters in international scientific collaboration (Oversight Committee for evaluation of metabolic consequences of HAART) with academia, industry, EMEA, FDA and community
Feb. – Oct. 2003
Gilead Sciences Germany
Interim Acting General Manager
- Leading German management team and operations during interim period
- Member of European management team
- Development and implementation of business turnaround-plan and budget review
Jan. 1999 – Dec. 2001
GlaxoSmithKline, HIV R&D, Greenford, U.K.
Global Clinical Development and Product Strategy
Director Medical Communication Strategy
- Member of international product development team for HIV protease inhibitor Agenerase (amprenavir)
- Member of international clinical review team for local phase IIIB/IV HIV study proposals
- Design, management and implementation of internal and external central medical communication around Agenerase for global launch
- Member of international product development team for anti-Malaria fixed dose combination Malarone (FDC atovaquone and proguanil)
- Development and execution of scientific communications and industry symposia at international conferences
- Co-chair international GSK project team on observational database in HIV and scientific collaboration with external observational databases; head of International Annual GSK sponsored HIV Cohorts Workshop
- Representation of GSK in international scientific collaboration (Oversight Committee for evaluation of metabolic consequences of HAART) with academia, industry, EMEA, FDA and community
- Development of medical training course for developing countries with new access to HIV-treatment
Jul. 1997 – Dec. 1998
Glaxo Wellcome Germany, Medical Department
Medical Advisor Antibiotics, HIV, Hepatitis and Malaria
Residency:
1994 – 1997
Bernhard-Nocht-Institute for Tropical Medicine, in- and outpatient clinic
Physician and Regional Co-ordinator of the German AIDS Study Group (GASG)
1992 – 1993
University Hospital Hamburg-Eppendorf, HIV outpatient clinic of the medical department
Physician
Further Education:
1993 Board-certified physician
1992 Course in tropical medicine at the Bernhard-Nocht-Institute, Hamburg
1985–92 Medical studies at the University of Hamburg
